The Valley Desk

NCT05607550 · Interventional trial

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Overall registry status Active not recruiting

Phase 3

Conditions Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations, Metastatic Non-Small Cell Lung Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov